ONCOLOGY DRUG PIPELINE ANALYSIS MARKET ANALYSIS
Key players are focused on mergers and collaborations to expand their share in the oncology drug pipeline market. For instance, in February 2018, Merck & Co., Inc. acquired Viralytics Ltd—an Australia-based oncolytic immunotherapies manufacturer— for US$ 394 million, to strengthen Merck & Co.’s presence in the immuno-oncology market.
Furthermore, in September 2018, Daiichi Sankyo Company, Limited, entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., to evaluate the combination of Daiichi Sankyo’s investigational Human Epidermal Growth Factor 2 (HER2) targeting antibody drug conjugate DS-8201 and Pembrolizumab. This combinational drug is intended to be used for metastatic breast and non-small cell lung cancers and is under clinical phase II development.
Key players operating in the global oncology pipeline drugs market include, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, Pfizer Inc., AbbVie Inc., Celgene Corporation, Novartis AG, Merck & Co., Inc., Sanofi, Eli Lilly & Co., GlaxoSmithKline, and Amgen Inc.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
